Latest News

Key Insights Using the 2 Stage Free Cash Flow to Equity, ARB fair value estimate is AU$38.00 ARB's AU$32.07 share price...

Volt Group Limited ( ASX:VPR ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...

Key Insights Origin Energy's significant individual investors ownership suggests that the key decisions are influenced...

Enterprise Products Partners (EPD) is back in focus after its general partner’s board approved a 2.8% increase in the quarterly cash distribution to $0.55 per unit, or $2.20 annualized, for the fourth quarter of 2025. See our latest analysis for Enterprise Products Partners. The distribution hike comes after a steady few months for the units, with the latest share price at $32.09 and a 90 day share price return of 4.22%. The 1 year total shareholder return of 5.58% and 5 year total...

On 12 January 2026, LiveDrop announced it is working with CGI to support Dutch Ministry of Defense projects by integrating its software-only, radio-frequency-free optical data transfer technology with CGI’s mission-critical IT and system integration capabilities. This collaboration strengthens CGI’s presence in secure, multi-domain defense IT, enhancing its role in handling sensitive information when conventional networks are unreliable or unavailable. Next, we will examine how this...

What Borr Drilling’s New Contracts Mean for Investors Borr Drilling (BORR) has drawn fresh attention after announcing new contract commitments for its Ran and Odin jack up rigs in Mexico and the United States, including additional extension options. See our latest analysis for Borr Drilling. These fresh contracts arrive as Borr Drilling’s share price sits at US$4.18, with a 90 day share price return of 58.33% and a 5 year total shareholder return of 143.80%. This suggests momentum has...

If you are wondering whether Ulta Beauty's share price still offers value after a strong run, this article will walk through what the current market price might imply about the stock. Ulta Beauty recently closed at US$661.49, with returns of 1.8% over 7 days, 10.0% over 30 days, 6.7% year to date, 63.7% over 1 year, 33.7% over 3 years, and 125.6% over 5 years. These figures naturally raise questions about what is already priced in and how much risk you are taking on at these levels. Recent...

Recent analyst actions around Brown & Brown (BRO) have turned attention to how a softening property and casualty insurance market could influence the company’s organic growth expectations, margins, and investor sentiment over the next few years. See our latest analysis for Brown & Brown. Brown & Brown’s recent analyst downgrades and concerns about softer property and casualty pricing sit against a share price of US$79.61, with a 90 day share price return of a 16% decline and a 1 year total...

Veracyte (VCYT) shares are in focus after the company released preliminary 2025 results alongside fresh guidance for 2026, outlining expected revenue ranges, testing growth and margin targets that give investors more visibility. See our latest analysis for Veracyte. Veracyte shares have been volatile around the recent guidance, with a 3.35% 1 day share price return to US$43.45 and a 24.93% 90 day share price return. The 1 year total shareholder return of 5.82% contrasts with a 62.80% total...

Markel Group (MKL) is in focus after Markel Insurance named Preeti Gureja as Chief Risk Officer for its US and Bermuda insurance operations. The move puts risk oversight and regulatory engagement at center stage. See our latest analysis for Markel Group. The appointment comes as Markel Group’s share price sits at US$2,119.42, with an 8.35% 90 day share price return and a 26.91% 1 year total shareholder return indicating momentum that has been building rather than fading. If this risk focused...

Why Blue Bird (BLBD) is on investors’ radar Blue Bird (BLBD) has caught investor attention after recent share price moves, with the stock showing mixed returns across different timeframes. That shift is prompting a closer look at how the business is currently positioned. See our latest analysis for Blue Bird. At a share price of $49.0, Blue Bird’s short term share price returns have softened over the last quarter, but its 1 year and 3 year total shareholder returns of 18.21% and roughly 3.3x...

In recent days, Barclays upgraded Kodiak Gas Services to an Overweight rating, while the company announced a dual listing on NYSE Texas and the full exit of EQT Infrastructure’s remaining stake via an underwritten public offering. These moves not only underscore sustained demand for Kodiak’s compression services tied to natural gas volume growth, but also mark a meaningful shift in its shareholder base and governance influence. We’ll now examine how Barclays’ more positive stance, alongside...

Ferrari (BIT:RACE) has completed its multiyear share buyback, repurchasing 6,015,933 shares, or 3.34% of its stock, for €2,000 million, including 717,508 shares between October and late December 2025. See our latest analysis for Ferrari. Ferrari’s €2,000 million buyback comes after a softer period for the shares, with a 1-year total shareholder return decline of 23.69% and a stronger 5-year total shareholder return of 85.87%. Recent 90-day share price returns show a 7.00% decline, suggesting...

AOP Health US, LLC recently expanded US access to its critical care drug Rapiblyk (landiolol) through Cardinal Health and other major distributors, allowing hospitals and health systems to source it via their usual channels. This broadened distribution highlights Cardinal Health’s role as a core conduit for complex therapies in acute care settings, reinforcing its importance in the specialty pharmaceutical supply chain. We’ll now examine how this wider Rapiblyk distribution through Cardinal...

Argan (AGX) is back on investor watchlists after Director Peter W Getsinger sold roughly US$3.38 million in shares, shortly after the company lifted its quarterly cash dividend by 33% and reported earnings ahead of expectations. See our latest analysis for Argan. Those events come after a sharp run, with Argan’s 1 year total shareholder return close to 100% and multi year total shareholder returns several times higher, even as recent share price returns have softened and short term momentum...

DOF Group ASA recently announced a 4-year contract, worth about US$150 million, for the RSV Skandi Commander with Petrobras in Brazil, with operations set to start in January 2027. This agreement is distinct because it combines an Autonomous Underwater Vehicle with a traditional Remote Operated Vehicle, highlighting DOF Group’s focus on higher‑spec, technology‑enabled offshore services. We’ll now examine how this new long-term Petrobras contract for Skandi Commander, with its AUV capability,...

Without a fresh headline to point to, First Majestic Silver (TSX:AG) has still been drawing attention as investors reassess its recent share performance, fundamentals and current valuation in the context of silver focused mining. See our latest analysis for First Majestic Silver. At a recent share price of CA$28.04, the stock has seen strong momentum, with a 30 day share price return of 27.92% and a very large 1 year total shareholder return of 234.75%. This suggests investors are reassessing...

Why XtalPi’s recent bond deal matters for equity investors XtalPi Holdings (SEHK:2228) recently announced a HK$2.866b zero coupon bond offering, while its shares saw profit taking after a strong past 3 months, as investors reassess AI drug discovery exposure. The bond is an unsubordinated, unsecured, callable zero coupon note priced at 100% of principal and due January 26, 2027. It was issued under Regulation S, which keeps equity investors focused on how the company allocates this fresh...

Thomson Reuters (TSX:TRI) has launched the Trust in AI Alliance through Thomson Reuters Labs, partnering with Anthropic, AWS, Google Cloud, and OpenAI to focus on trustworthy, agentic AI systems in high-stakes professional settings. See our latest analysis for Thomson Reuters. The Trust in AI Alliance announcement comes after a softer patch in the share price, with a 20.07% 90 day share price return decline and a 1 year total shareholder return decline of 18.13%. However, the 5 year total...

Event context and why Aktis Oncology is on investors’ radar Aktis Oncology (AKTS) recently drew attention after a daily share move of about 3%. This has prompted investors to look more closely at how its clinical stage radiopharmaceutical pipeline and current financial profile line up. See our latest analysis for Aktis Oncology. While the latest 1 day share price return of 2.90% was negative, the year to date share price return of 20.83% suggests earlier momentum that investors are now...

Installed Building Products (IBP) has priced and completed a US$500 million fixed rate senior unsecured notes offering due 2034, and has also agreed to repurchase 150,000 shares from an entity owned by its CEO. See our latest analysis for Installed Building Products. These financing moves and the CEO share repurchase come as Installed Building Products trades at US$302.97, with recent momentum reflected in a 10.50% 7 day share price return and a 76.15% 1 year total shareholder return,...

Rising short interest puts fresh focus on Annaly Capital Management (NLY) Recent data shows an 11.63% rise in short interest for Annaly Capital Management (NLY), with 13.08 million shares now sold short, or 1.92% of the float, drawing increased attention to bearish positioning. See our latest analysis for Annaly Capital Management. Despite the recent pickup in bearish positioning, Annaly Capital Management’s share price has held at US$23.19, with a 90 day share price return of 11.92% and a 1...

Vericel Corporation recently issued preliminary, unaudited guidance for the fourth quarter and full year 2025, pointing to 23% quarterly revenue and MACI sales growth and approximately US$276,000,000 in total net revenue, alongside GAAP net income profitability for a second consecutive year. This combination of double-digit top-line expansion and repeat GAAP profitability suggests the company’s regenerative therapies model is scaling operationally as it grows. With Vericel highlighting 23%...

Concentrix Corporation recently reported fourth-quarter and full-year 2025 results showing revenue rising to US$2,552.93 million and US$9.83 billion respectively, but swinging from net income to a very large net loss, while also issuing new 2026 guidance and declaring a US$0.36 quarterly dividend. This combination of higher sales, sharp profitability deterioration, continued dividend payments, and quantified operating-income guidance gives investors fresh insight into how Concentrix is...